Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

SANOFI (SAN)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweets
OFFRE

Sanofi : France's Sanofi sells 12 brands to Charterhouse's Cooper-Vemedia

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/16/2018 | 08:44am CEST
FILE PHOTO:French multinational pharmaceutical company SANOFI logo is seen at the headquarters in Paris

PARIS (Reuters) - French healthcare and drugs group Sanofi has agreed to sell a portfolio of 12 pharmaceutical brands to Charterhouse Capital Partners' Cooper-Vemedia drugs manufacturing arm for 158 million euros (£136.6 million), the companies said on Monday.

PARIS (Reuters) - French healthcare and drugs group Sanofi has agreed to sell a portfolio of 12 pharmaceutical brands to Charterhouse Capital Partners' Cooper-Vemedia drugs manufacturing arm for 158 million euros (£136.6 million), the companies said on Monday.

Sanofi said the sale formed part of its strategy to focus on its main businesses in areas such as allergy treatments and nutritional products, and to simplify its business portfolio.

Private equity and investment firm Charterhouse Capital said the acquisition would help build up the healthcare portfolio of Cooper-Vemedia, which is a European drug manufacturer and distributor.

(Reporting by Sudip Kar-Gupta; Editing by Edmund Blair)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SANOFI
09/22SANOFI : Catholic Church partner on diabetes, hypertension management
AQ
09/20STUDIES FROM SANOFI UPDATE CURRENT D : is...
AQ
09/20SANOFI : New Zika Virus Findings from Sanofi Pasteur Discussed
AQ
09/20SANOFI : Findings on FDA Actions Detailed by Investigators at Genzyme Corporatio..
AQ
09/20SANOFI : Recent Research from Sanofi Pasteur Highlight Findings in Vaccines (Al-..
AQ
09/20SANOFI : Coughs Up $25 Million to Settle SEC FCPA Charges
AQ
09/20SANOFI : Coughs Up $25 Million to Settle SEC FCPA Charges
AQ
09/20SANOFI : Catholic Partner to Address Diabetes, Hypertension in Nigeria
AQ
09/19SANOFI : Galera raises $150 million, will hire staff for cancer-radiation side-e..
AQ
09/18SANOFI : unveils eczema drug data, as regulators mull label expansion
AQ
More news
News from SeekingAlpha
09/21Feds looking into free services from drug makers - WSJ 
09/20Arvinas Holding Prepares Terms For $100 Million IPO 
09/15Regeneron and Sanofi's Dupixent shows treatment benefit in adolescents with a.. 
09/15STOCKS TO WATCH : Oracle Looks To Lift Tech Sector 
09/14Sanofi (SNY) Presents at Bank of America Merrill Lynch Global Healthcare Conf.. 
STOCK PICK
At a crossroads
Financials (€)
Sales 2018 35 107 M
EBIT 2018 8 381 M
Net income 2018 5 005 M
Debt 2018 16 227 M
Yield 2018 4,13%
P/E ratio 2018 18,08
P/E ratio 2019 16,81
EV / Sales 2018 3,12x
EV / Sales 2019 3,01x
Capitalization 93 247 M
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 80,2 €
Spread / Average Target 7,7%
EPS Revisions
Managers
NameTitle
Olivier Brandicourt Chief Executive Officer & Director
Serge Weinberg Chairman
Jérôme Contamine Chief Financial Officer & Executive VP-Finance
Ameet Nathwani Executive Vice President-Medical Affairs
John C. Reed Head-Global Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI3.69%109 540
JOHNSON & JOHNSON1.62%383 312
PFIZER21.65%258 285
NOVARTIS-0.63%216 108
ROCHE HOLDING LTD.-4.60%211 501
MERCK AND COMPANY25.79%189 092